摘要
目的评价新一代氟喹诺酮类药物莫西沙星对耐多药肺结核病(MDR-PTB)的治疗作用。方法132例MDR-PTB患者随机分为2组:治疗组(I组)用莫西沙星0.4g,每日1次;对照组(II组)用左氧氟沙星0.4g,每日1次,疗程12月,同时辅以其他抗痨药物治疗,126例完成疗程。结果治疗组痰菌阴转率明显高于对照组(P<0.05),影像吸收率、副作用2组间差异无显著性(P>0.05)。结论莫西沙星是一种安全、有效的抗MDR-PTB药物。
Objective To evaluate the therapeutic effect of moxifloxacin and levofloxacin on multiple drug resistant pulmonary tuberculosis（MDR-PTB）. Methods 132 patients with MDR-PTB were randomly divided into two groups. The trial group was treated with moxifloxacin 0.4g once a day, while the control group was treated with levofloxacin 0.4g once a day, with a treatment course of 12 months, at the same time the other anti-tuberculosis drugs were also used for both groups. 126 patients finished the treatment course. Results The sputum negative conversion rate in trial group was significanfly higher than those in control group（ P 〈 0.05）. There were no significant differences in imaginga bsorption rate and side effects between two groups（ P 〉 0.05）. Conclusion Moxifloxacin is an effective drug in treating MDR-PTB.
出处
《河北医药》
CAS
2007年第6期557-558,共2页
Hebei Medical Journal
基金
河北省科技攻关计划项目(编号:062761918)
关键词
莫西沙星
左氧氟沙星
耐多药肺结核病
临床疗效
moxifloxacin
levofloxacin
multiple drug resistant pulmonary tuberculosis
clinical efficacy
